{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:35:04Z","timestamp":1790112904709,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.vaccine.2025.126780","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T03:47:45Z","timestamp":1738208865000},"page":"126780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferrets"],"prefix":"10.1016","volume":"49","author":[{"given":"Masayuki","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Tsujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Nakajima-Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuteru","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Dohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aki","family":"Ejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Yamamoto-Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Nojiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou","family":"Saiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Omoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2025.126780_bb0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/vaccines9020075","article-title":"Adjuvantation of influenza vaccines to induce cross-protective immunity","volume":"9","author":"Li","year":"2021","journal-title":"Vaccines"},{"issue":"31","key":"10.1016\/j.vaccine.2025.126780_bb0020","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1016\/j.vaccine.2022.05.081","article-title":"Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys","volume":"40","author":"Hashimoto","year":"2022","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2025.126780_bb0025","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.1016\/j.vaccine.2022.10.092","article-title":"Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 omicron subvariants in cynomolgus macaques","volume":"40","author":"Hashimoto","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126780_bb0030","doi-asserted-by":"crossref","first-page":"20861","DOI":"10.1038\/s41598-022-25418-5","article-title":"Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice","volume":"12","author":"Homma","year":"2022","journal-title":"Sci Rep"},{"issue":"27","key":"10.1016\/j.vaccine.2025.126780_bb0035","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1016\/j.vaccine.2022.04.054","article-title":"Phase 1\/2 clinical trial of COVID-19 vaccine in Japanese participants: a report of interim findings","volume":"40","author":"Iwata","year":"2022","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2025.126780_bb0040","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1016\/j.vaccine.2022.06.032","article-title":"Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: an interim report of phase 2\/3, randomized, observer-blinded, noninferiority study","volume":"40","author":"Shinkai","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126780_bb0045","doi-asserted-by":"crossref","first-page":"9830","DOI":"10.1038\/s41598-024-57308-3","article-title":"A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults","volume":"14","author":"Iwata","year":"2024","journal-title":"Sci Rep"},{"issue":"15","key":"10.1016\/j.vaccine.2025.126780_bb0050","article-title":"Safety and immunogenicity of a booster dose of S-268019-b: interim findings of a phase 3, open-label clinical study in Japan","volume":"18","author":"Sonoyama","year":"2023","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2025.126780_bb0055","doi-asserted-by":"crossref","first-page":"1116238","DOI":"10.3389\/fimmu.2023.1116238","article-title":"A-910823, a squalene-based emulsion adjuvant, induces T follicular helper cells and humoral immune responses via \u03b1-tocopherol component","volume":"14","author":"Yoshioka","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126780_bb0060","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41467-023-37128-1","article-title":"Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain","volume":"14","author":"Takano","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2025.126780_bb0065","article-title":"Longitudinal analysis of B- and T-cell responses to SARS-CoV-2 recombinant S-protein vaccine S-268019-b in phase 1\/2 priming and booster study","author":"Fujitani","year":"2024","journal-title":"medRxiv"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126780_bb0070","doi-asserted-by":"crossref","first-page":"e01113","DOI":"10.1128\/mBio.01113-18","article-title":"Moving forward: recent developments for the ferret biomedical research model","volume":"9","author":"Albrecht","year":"2018","journal-title":"mBio"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126780_bb0075","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.micinf.2011.01.014","article-title":"The contribution of animal models to the understanding of the host range and virulence of influenza a viruses","volume":"13","author":"O\u2019Donnell","year":"2011","journal-title":"Microbes Infect"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126780_bb0080","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/17460441.2018.1540586","article-title":"Animal models used to assess influenza antivirals","volume":"13","author":"Mifsud","year":"2018","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126780_bb0085","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/s42003-022-04005-4","article-title":"Assessing the fitness of a dual-antiviral drug resistant human influenza virus in the ferret model","volume":"5","author":"Stannard","year":"2022","journal-title":"Commun Biol"},{"issue":"15","key":"10.1016\/j.vaccine.2025.126780_bb0090","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1128\/JVI.77.15.8418-8425.2003","article-title":"Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors","volume":"77","author":"Matrosovich","year":"2003","journal-title":"J Virol"},{"issue":"129","key":"10.1016\/j.vaccine.2025.126780_bb0095","doi-asserted-by":"crossref","DOI":"10.3791\/56448","article-title":"Measuring influenza neutralizing antibody responses to a(H3N2) viruses in human sera by microneutralization assays using MDCK-SIAT1 cells","volume":"22","author":"Gross","year":"2017","journal-title":"J Vis Exp"},{"key":"10.1016\/j.vaccine.2025.126780_bb0100","author":"Global Influenza Programme (who.int)"},{"key":"10.1016\/j.vaccine.2025.126780_bb0105","article-title":"Safety and immunogenicity of mRNA-1010, an investigational seasonal influenza vaccine, in healthy adults: final results from a phase 1\/2 randomized trial","author":"Ananworanich","year":"2024","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126780_bb0110","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","article-title":"Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine Administration in Rhesus Macaques","volume":"25","author":"Liang","year":"2017","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126780_bb0115","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41551-019-0378-3","article-title":"Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging","volume":"3","author":"Lindsay","year":"2019","journal-title":"Nat Biomed Eng"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126780_bb0120","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.immuni.2020.11.009","article-title":"SARS-CoV-2 mRNA vaccines Foster potent antigen-specific germinal center responses associated with neutralizing antibody generation","volume":"53","author":"Lederer","year":"2020","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126780_bb0125","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41590-022-01168-4","article-title":"Making innate sense of mRNA vaccine adjuvanticity","volume":"23","author":"Kobiyama","year":"2022","journal-title":"Nat Immunol"},{"issue":"25","key":"10.1016\/j.vaccine.2025.126780_bb0130","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126780_bb0135","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126780_bb0140","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.it.2017.08.003","article-title":"From original antigenic sin to the universal influenza virus vaccine","volume":"39","author":"Henry","year":"2018","journal-title":"Trends Immunol"},{"issue":"10","key":"10.1016\/j.vaccine.2025.126780_bb0145","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/14760584.2019.1675519","article-title":"Preexisting influenza specific immunity and vaccine effectiveness","volume":"18","author":"Jang","year":"2019","journal-title":"Expert Rev Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25000775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25000775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:18:41Z","timestamp":1741346321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25000775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":27,"alternative-id":["S0264410X25000775"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126780","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferrets","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126780","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126780"}}